Introduction
Leber congenital amaurosis (LCA [MIM 204000]) is a set of inherited, early-onset retinal dystrophies that affect approximately 1:50,000 people in the general U.S. population and account for more than 5% of all retinal dystrophies. 1, 2 The clinical phenotypes of LCA are characterized by severe visual loss at birth, nystagmus, a variety of fundus changes, and minimal or absent recordable responses on the electroretinogram (ERG), usually with an autosomal-recessive pattern of inheritance. 3 Consistent with this clinical variability, the molecular basis for LCA is also heterogeneous, with mutations described in fourteen genes. Functional studies of previously identified genes indicate that they act in strikingly diverse functional pathways underlying the disease, including retina development (CRB1 18 ). In addition, the function of RD3 remains unclear. 19 Because of these profound differences in the underlying mechanisms of LCA, accurate molecular diagnosis of the disease is essential for the proper management of LCA patients. Therefore, identifying new genes and pathways and ascertaining the full complement of genes responsible for LCA are fundamental steps toward developing appropriate treatments for this devastating disease. Knowledge obtained from LCA studies also offers insights into the pathogenesis and the molecular mechanisms underlying other retinal dystrophies, which are often shared. 20 LCA shares several important clinical features with other retinal dystrophies, such as retinitis pigmentosa (RP [MIM 500004]). In fact, LCA was first described as an ''intrauterine'' form of RP. 1 Juvenile RP, unlike LCA, initially has a milder phenotype. It is often characterized by the onset of nyctalopia (night blindness), visual-field narrowing, and eventual visual-acuity loss, with or without nystagmus. Given the substantial clinical overlap with juvenile RP, it is expected that these two diseases might be caused by mutations in the same gene. 21 Indeed, at least seven of the known LCA disease genes, including CRX, CRB1, RPE65, RDH12, LRAT, MERTK, and TULP1, have also been linked to the clinical appearance of juvenile RP in other families. 22 Similarly, mutations in LCA genes may also be associated with other retinal diseases, such as cone-rod dystrophy (CRX,
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AIPL1, 23 and GUCY2D 8, 9 ), and even systemic diseases, such as Joubert syndrome, Meckel syndrome, and BardetBiedl syndrome (CEP290 [24] [25] [26] ).
In addition to these 14 LCA genes, two genetic loci (LCA3 at 14q24 and LCA9 at 1p36) have been identified, but the underlying genes remain unknown. 27, 28 The exclusion of RDH12 as an LCA3 disease gene suggests that another retinal dystrophy disease gene is responsible for the LCA3 phenotype. 29 In this report, we identified five new families that we mapped to the LCA3 locus, utilizing fine mapping of the critical region through homozygosity mapping and single-nucleotide polymorphism (SNP) microarray technology. 21 We identified homozygous nonsense and frameshift mutations in a positional candidate gene, SPATA7 (spermatogenesis associated protein 7 [MIM 609868]) by direct Sanger sequencing. SPATA7 encodes a highly conserved protein containing a single transmembrane domain. To better understand its normal function in the retina, we examined the expression pattern of Spata7 in the developing and mature mouse retina, and we found that it is expressed in multiple retinal layers in the adult mouse retina.
Subjects and Methods

Study Subjects
We obtained blood samples and pedigrees after receiving informed consent from all individuals. 
STR and SNP Genotyping and Sequencing
A list of microsatellite markers between D14S61 and D14S1015 were selected from the UCSC Human Genome Browser. For genotyping, primers specific for each marker were obtained from the human genome, and a universal tail was added to the 5 0 primer (5 0 -CTCGGTGCAGAGCATCATGC). PCR reactions were performed according to a standard protocol, 30 and products were size fractionated on an ABI 3700 capillary electrophoresis system and analyzed with the ABI GeneMapping software. A genomewide scan of >318,000 tag SNPs was conducted on one affected member from the KKESH-060 and KKESH-019 families with the Illumina Hap300-Duo Bead Arrays, in accordance with the manufacturer's protocols. Homozygous regions were visualized and identified with the Bead Studio software package. For identification of mutations in candidate genes, a direct PCRsequencing approach was used. All exons and their splice junctions for each candidate gene (total of 9) in the critical LCA3 region were amplified by PCR. The completeness and quality of the sequence was ensured by the design of primers from intron sequences so that the entire exon and at least 50 bp of intron DNA on each side of each exon were amplified for detection of potential mutations. For large exons, more than one pair of primers amplified overlapping regions spanning both the exon and its splice sites. Sequences for the primers of the 12 exons and splice junctions of SPATA7 are included in 
RNA In Situ Hybridization and Immunohistochemistry
An RNA in situ probe specific to Spata7 (exons 8-12) was prepared according to a previously published protocol 31 (probe 5 0 -primer:
. Total RNA was extracted from freshly isolated C57 wild-type (WT) eyes homogenized in Trizol (Invitrogen) and purified according to the manufacturer's instructions. A Spata7 cDNA fragment was cloned into the EcoRI site of the TOPO cloning vector (Invitrogen). Antisense riboprobe constructs were linearized with XhoI and transcribed with SP6 RNA polymerase (DIG RNA Labeling Kit, Roche). RNA in situ hybridization (ISH) and antibody staining was conducted on WT E16.5, P4, and P21 and C57Bl/6 129SvEv F1 hybrid eye sections. WT eyes were collected, fixed in 4% paraformaldehyde overnight, dehydrated in ethanol, and paraffin embedded. For ISH, 5 mm eye sections were cut, dewaxed in xylene, then rehydrated and treated with proteinase K. Hybridization incubations were carried out in hybridization buffer (50% formamide, 5XSSC [pH 4.5-5.0], 1% SDS, 50 mg/ml yeast tRNA, 50 mg/ml heparin) at 65 C overnight, followed by three 30-min washes with prewarmed washing buffer (50% formamide, 1XSSC [pH 4.5-5.0], 1% SDS) at 65 C. The slides were then incubated with alkaline phosphatase-conjugated anti-DIG (Roche) in 13 MABT (100 mM maleic acid, 150 mM NaCl, 0.1% Tween 20, pH 7.5), 2% BRB (Roche) and 10% goat serum overnight at room temperature. After five washes (30 min each) with MABT buffer and one wash with NTMT (100 mM Tris-HCl [pH 9.5], 100 mM NaCl, 50 mM MgCl2, 0.1% Tween 20, and 0.048% levamisole), hybridization signals were visualized by incubation with BM Purple (Roche) at room temperature for the desired time.
For immunohistochemistry (IHC), antigen retrieval was performed by boiling of 10 mm sections in 0.01 M citrate buffer twice for 2 min, followed by cooling for 40 min at room temperature. Slides were washed in PBS, incubated for 1 hr at room temperature in hybridization buffer (10% normal goat serum, 0.1% Triton X-100, PBS), then incubated overnight in primary antibody diluted in hybridization buffer. Slides were then washed in PBS, incubated with secondary antibody diluted in hybridization buffer at room temperature for 2 hr, washed in PBS, and coverslipped. For testing the specificity of the Spata7 antibody, a blocking experiment was performed. A GST-Spata7 fusion protein was constructed by insertion of a mouse Spata7 open reading frame into the multiple cloning site of the pGEX-4T-1 vector. The fusion protein was induced in the presence of 0.5 mM IPTG at 26 C for 8 hr and purified with the use of Glutathione Sepharose 4B as described in manufacturers' instructions (Amersham Bioscience). The in vitro antibody-depletion experiments were performed with purified GST or GST-Spata7 fusion proteins bound to Glutathione Sepharose 4B. Spata7 antibody was incubated with 50 ml of GST beads, containing either GST-Spata7 or GST, at 4 C overnight, then the depleted antibody was used for IHC as described above. Dilutions and sources of antibodies were: mouse anti-rhodopsin (B6-30N) (1:100, a generous gift from W. Clay Smith), rabbit antiSpata7 (1:7.5, Proteintech Group), Alexa anti-mouse (1:400, Molecular Probes), Cy5 anti-rabbit (1:400, Jackson Immunochemicals). Fluorescent images were captured with a Zeiss LSM 510 confocal microscope and processed with Image J and Adobe Photoshop software.
Results
Fine Mapping of the LCA3 Locus Previously, the LCA3 locus was mapped to chromosome 14q24 in a large, consanguineous LCA family (KKESH-019) from Saudi Arabia with 15 affected and 42 unaffected members. 27 The critical region was initially identified by homozygosity mapping with STR markers. However, the distal boundary of the critical region was not well mapped, because there was no genotyping within a 10 Mb segment between D14S74 and D14S68. More importantly, at least four recombinants have been reported for marker D14S68, indicating that the critical region could be greatly reduced by genotyping of additional markers within the distal region. We therefore conducted fine mapping of the distal boundary of the critical region with additional STR markers between D14S74 and D14S68 (Table S1 ). On the basis of these genotyping results, all affected members of KKESH-019 were found to be homozygous between markers D14S1022 and D14S1005 ( Figure S1 ). We then used these STR markers to scan additional LCA patient cohorts for new LCA families that may map to the LCA3 region. In this manner, the KKESH-060 family from Saudi Arabia was also identified as an LCA3 family 29 ( Figure S2 ). All three affected members from the KKESH-060 family are homozygous from markers D14S61 to D14S1066. To further confirm the homozygous region, DNA from one affected subject from each of these two families was genotyped by whole-genome SNP analysis with the Illumina SNP array. The new SNP genotyping results are consistent with the previous STR genotyping data, and affected subjects from these two families are homozygous for the LCA3 locus at Chromosome 14q24 ( Figure S3) . Intersection of the homozygous region from these two LCA families defines a critical region of 3.8 Mb between markers D14S1022 and D14S1005.
SPATA7 Is Another LCA and Juvenile RP Gene A total of nine annotated genes are included within the newly defined LCA3 critical region based on NCBI Build 36.1 ( Figure 1A ). Direct Sanger sequencing of all exons of all nine candidate genes from both LCA3 families identified a nonsense mutation in SPATA7, a conserved gene containing 12 exons, in the KKESH-060 family ( Figure 1C ). All three affected members of KKESH-060 are homozygous for a nonsense mutation in the fifth exon (c.322C/T; p.R108X). The mutation segregates with the disease in this family, given that the three affected individuals are homozygous for the same mutation whereas the unaffected members are either heterozygous or do not carry the mutation ( Figure 1C and Figure S2) . Furthermore, the nonsense mutation is not a common SNP, because it is not recorded in the dbSNP database. Consistent with the above information, the mutation was not detected in 150 normal control samples, including 50 Saudi Arabian and 100 European samples, through direct sequencing of all exons of SPATA7 (data not shown). No exonic mutation was found in KKESH-019 (see Discussion for details). To further confirm that SPATA7 is an LCA disease gene, we sought to identify additional LCA patients with SPATA7 mutations. By homozygosity mapping with genome-wide SNP microarrays, five additional patients with LCA or juvenile RP were recently found to be homozygous at the LCA3 locus ( 21 and unpublished data). Mutation analysis of SPATA7 revealed the same R108X nonsense mutation (found in the KKESH-060 family) in a Dutch LCA patient (no. 12811) ( Figure 1C ). On the basis of the STR genotyping result, the mutation analysis suggests that patient no. 12811 does not share the same haplotype with the patients from KKESH-060 (data not shown). This may be caused by a rapid decay of CpG sites, given that the 5-methylcytosine at CpG sites mutates unidirectionally to thymine by spontaneous deamination at a much higher transition rate compared to non-CpG dinucleotides. 32 Finally, a homozygous frameshift mutation (c.961dupA; p.P321TfsX326) in exon 8 of SPATA7 was found in an LCA patient (no. 1617) of Middle Eastern origin ( Figure 1C ). In addition, a Portuguese patient (no. 28608) with juvenile RP was found to be homozygous for a nonsense mutation (c.1183C/T; p.R395X) in exon 11 of SPATA7 ( Figure 1D ). Finally, a homozygous frameshift mutation in exon 12 (c.1546delA; p.Q465fsX505) was identified in a French Canadian patient (no. 1348) with juvenile RP ( Figure 1D ). All mutations segregated with the disease in the affected families were not found in the 150 normal controls or in the SNP databases. In contrast to the two SPATA7 mutations identified in LCA patients (p.R108X and p.P321TfsX326), the two juvenile RP mutations are close to the C-terminal part of the SPATA7 protein.
Although carrying mutations in the same gene, the two juvenile RP patients present a clinical phenotype that is less severe than that of LCA patients. All three LCA patients from the KKESH-060 family showed poor visual fixation and function from birth and subsequently developed nystagmus, hyperopic astigmatism, and a nondetectable electroretinogram. A Dutch patient (no. 12811) was first seen in our clinic at age 6. She has had visual problems since birth, showing rotating nystagmus, peripheral chorio-retinal atrophy, and bone spicules pigmentation. In contrast, a 7-year-old Portuguese girl (no. 28608, diagnosed with juvenile RP) has excellent visual acuity (20/20) , and nystagmus is absent. She developed earlyonset nyctalopia before age 2 and has 5 visual fields (Goldmann) and nondetectable ERGs (Figure 2A) . Similarly, a juvenile RP patient (no. 1348) from a French Canadian family was found to have hand-motion vision at age 55. He reported seeing normally as a child and then declining, developing night blindness and nystagmus. This patient was found to have advanced retinal pigmentary degeneration, with narrow arterioles, optic disc pallor, and a small maculopathy on exam at age 55 years ( Figure 2B ). The ERG was nondetectable, and the visual fields were reduced to 5 with the V4e target.
Spata7 Is a Highly Conserved, Vertebrate-Specific Protein Expressed in the Mature Retina Human SPATA7 comprises 12 exons ( Figure 1B ) that encode a protein of 599 amino acids. SPATA7 is conserved from sea urchin to human but is absent in lower eukaryotes, such as insects and fungi ( Figure S4) . A single-pass transmembrane domain is predicted by the PSIPred program ( Figure 1B) . However, no previously known functional domains have been identified.
Studies of gene-expression profiles, including the use of microarrays and databases of expressed sequence tags, indicate that SPATA7 is expressed in the human retina. We examined the expression pattern of Spata7 in the mouse retina at several developmental stages, using both mRNA ISH and IHC. Mouse retinas were stained at three developmental time points, E16.5, P4, and P21, corresponding to early, middle, and fully developed retinas. On the basis of the ISH results, Spata7 is not detectable in the E16.5 or P4 mouse retina ( Figures 3A and 3B) , suggesting that Spata7 is not required for early retinal development. In contrast, expression is observed in the P21 mature mouse retina, suggesting that Spata7 may be involved in normal retinal function rather than development ( Figure 3C ). Consistent with ISH results, little Spata7 protein is detected in the P4 mouse retina by IHC ( Figures  3D-3F) . In contrast, expression of Spata7 protein is observed in multiple layers of the P21 retina, including the ganglion cell and inner nuclear layers, and inner segments of photoreceptors ( Figures 3G-3L ).
Discussion
It is interesting to note that mutations in SPATA7 cause LCA and RP, two overlapping but distinct human retinal diseases. A fascinating aspect of human retinal diseases is the enormous heterogeneity in terms of both clinical phenotypes and their underlying molecular mechanisms. Undoubtedly complex genetic inheritance contributes to this heterogeneity. For example, digenic triallelic inheritance has been observed in some families segregating the Bardet-Biedl phenotype, in which inheritance of a mutation in a second gene is required for an individual who has two mutations in the first gene to exhibit a clinical phenotype or to modify the severity of the primary phenotype. 33 Another major cause for heterogeneity is differential severity of mutant alleles at a single locus, as is likely in our study. We have isolated multiple loss-of-function mutations in SPATA7 that cause either LCA or juvenile RP. Consistent with the observation that LCA has a more severe clinical phenotype than juvenile RP, the mutant alleles associated with LCA are likely to be more severe loss-of-function alleles than those associated with juvenile RP. The two alleles found in our LCA patients are nonsense mutations located in the middle of the SPATA7 coding region (exons 5 and 8; Figure 1B ). These two mutations will probably cause relatively early protein truncations and therefore are likely to be severe loss-of-function alleles because of nonsense-mediated decay and destruction of message. 34, 35 In contrast, the two mutations that we identified in the juvenile RP patients are located in the last two exons of SPATA7. Because these two mutations are very close to the C terminus of the protein, they will probably cause only truncation of a small portion of the protein product, although it is possible that the mutation in the second-to-last exon could cause a reduction of SPATA7 mRNA levels as a result of nonsense-mediated decay. 34, 35 Therefore, our findings provide suggestive evidence of a correlation between the severity of mutant alleles in SPATA7 and the resulting clinical phenotype. It is conceivable that many human diseases are caused not only by coding mutations but by noncoding-region mutations that may affect gene expression. For example, the most prominent mutation in the LCA gene CEP290 is an intron mutation that causes aberrant splicing of the transcript.
14 Our data suggest that the initial LCA3 family, KKESH-019, probably carries a mutation outside of the coding region of the SPATA7 gene rather than in other genes in this locus. All genes within the critical region defined by the KKESH-019 family alone have been sequenced, and no mutations were identified within exonic sequences in the KKESH-019 family. To identify a disease-causing mutation in the KKESH-019 family, we first sequenced the 5 0 and 3 0 UTR regions of SPATA7, but we found no change. Furthermore, to test for possible chromosome rearrangements at the SPATA7 locus in this family, we used tiling of 3 kb PCR amplicons to analyze the entire SPATA7 locus, including about 50 kb beyond the transcription unit, from an affected KKESH-019 patient, but we found no obvious changes compared to WT. This result suggests that no major chromosomal rearrangements, insertions, or deletions are present at the SPATA7 locus in the KKESH-019 family. However, sequencing of these PCR products did identify several changes, including single-nucleotide substitutions and small insertions and deletions in the promoter region and introns of SPATA7. Because RNA samples from the KKESH-019 family are not available, we are not able to test whether these changes can indeed affect SPATA7 expression in the patients. Additional experiments will need to be carried to determine whether any of these noncoding changes cause defects in normal SPATA7 expression.
SPATA7 is a gene that was first identified in human spermatocytes. On the basis of its expression pattern, SPATA7 may be involved in preparing chromatin in early meiotic prophase nuclei for the initiation of meiotic recombination. 36 We found that in addition to its expression in testis, Spata7 is expressed in multiple layers of the mature mouse retina. On the basis of its expression pattern in the retina, it would seem that SPATA7 is not a typical cilium protein, despite its potential function in both sperm and retina. Close examination of SPATA7 expression in the retina indicates that the protein is not enriched at the junction between the inner and outer segments of photoreceptor cells, where the cilium is located. Rather, the protein shows a uniform distribution in the cytoplasm of the inner segment. Given this information, together with the relatively late onset of SPATA7 expression in the retina, we speculate that SPATA7 may be involved a novel pathway. Additional studies need to be carried out to reveal the function of SPATA7. In summary, we report the cloning of another LCA disease gene, SPATA7. The LCA3 locus was first mapped to chromosome 14 more than 10 years ago, but the causal gene had not been identified. Through the combination of homozygosity mapping by SNP arrays and direct Sanger sequencing of all positional candidate genes within the LCA3 critical region, we identified SPATA7 as the diseasecausing gene. Given that we identified multiple mutations in distinct ethnic groups, this gene appears to be an important player in LCA and in other retinal diseases, such as juvenile RP. As a gene that is linked to multiple human diseases, SPATA7 offers opportunities for uncovering novel insights into human pathogenesis.
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